Combination of dysfunctional beliefs about sleep and excessive daytime sleepiness as a psychobehavioral characteristic of comorbid insomnia and sleep apnea
Abstract
Comorbid insomnia and sleep apnea (COMISA) is associated with poorer clinical outcomes than chronic insomnia disorder (CID) or obstructive sleep apnea (OSA) alone. However, the psychobehavioral characteristics that differentiate COMISA remain unclear. We aimed to examine the combined roles of dysfunctional beliefs and attitudes about sleep (DBAS) and excessive daytime sleepiness (EDS) in COMISA. We analyzed data from 283 patients (42 with CID alone, 166 with OSA alone, 75 with COMISA) from the National Center of Neurology and Psychiatry database, a component of a polysomnography databank for sleep disorders in Japan. DBAS was assessed using the 16-item DBAS scale (0-160 points), and EDS was measured using the Epworth Sleepiness Scale (ESS; 0-24 points). Participants were categorized into four groups based on median ESS and DBAS scale scores (medians: 90 and 9, respectively): low ESS/low DBAS, low ESS/high DBAS, high ESS/low DBAS, and high ESS/high DBAS. Logistic regression analyses, adjusting for multiple covariates, such as age, sex, and body mass index, were conducted. The high ESS/high DBAS phenotype was significantly associated with COMISA relative to the low ESS/low DBAS reference group in comparisons with both CID and OSA. The low ESS/high DBAS phenotype was also significantly associated with COMISA compared with OSA. Coexisting elevated DBAS and EDS appear to represent a distinct psychobehavioral phenotype distinguishing COMISA from CID or OSA alone. Assessing DBAS in…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.